ATE7223T1 - Durch sulfamoylgruppen substituierte phenethylamin-derivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen. - Google Patents

Durch sulfamoylgruppen substituierte phenethylamin-derivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.

Info

Publication number
ATE7223T1
ATE7223T1 AT81300431T AT81300431T ATE7223T1 AT E7223 T1 ATE7223 T1 AT E7223T1 AT 81300431 T AT81300431 T AT 81300431T AT 81300431 T AT81300431 T AT 81300431T AT E7223 T1 ATE7223 T1 AT E7223T1
Authority
AT
Austria
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
derivatives substituted
sulfamoyl groups
Prior art date
Application number
AT81300431T
Other languages
English (en)
Inventor
Kazuo Imai
Kunihiro Niigata
Takashi Fujikura
Shinichi Hashimoto
Toichi Takenaka
Original Assignee
Yamanouchi Pharmaceutical Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11859488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE7223(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharmaceutical Co. Ltd. filed Critical Yamanouchi Pharmaceutical Co. Ltd.
Application granted granted Critical
Publication of ATE7223T1 publication Critical patent/ATE7223T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/10—Radicals substituted by singly bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT81300431T 1980-02-08 1981-02-02 Durch sulfamoylgruppen substituierte phenethylamin-derivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen. ATE7223T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1438280A JPS56110665A (en) 1980-02-08 1980-02-08 Sulfamoyl-substituted phenetylamine derivative and its preparation
EP81300431A EP0034432B1 (de) 1980-02-08 1981-02-02 Durch Sulfamoylgruppen substituierte Phenethylamin-Derivate, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen

Publications (1)

Publication Number Publication Date
ATE7223T1 true ATE7223T1 (de) 1984-05-15

Family

ID=11859488

Family Applications (1)

Application Number Title Priority Date Filing Date
AT81300431T ATE7223T1 (de) 1980-02-08 1981-02-02 Durch sulfamoylgruppen substituierte phenethylamin-derivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.

Country Status (17)

Country Link
US (6) US4373106A (de)
EP (1) EP0034432B1 (de)
JP (1) JPS56110665A (de)
AR (2) AR227533A1 (de)
AT (1) ATE7223T1 (de)
AU (1) AU541720B2 (de)
CA (1) CA1177849A (de)
DE (2) DE19675042I2 (de)
ES (1) ES499224A0 (de)
GR (1) GR73827B (de)
IE (1) IE50862B1 (de)
LU (1) LU90000I2 (de)
MX (2) MX6859E (de)
NL (1) NL950014I2 (de)
PT (1) PT72460B (de)
SU (3) SU1082320A3 (de)
UA (3) UA5990A1 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
EP0091749A3 (de) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
JPS62114952A (ja) * 1985-11-13 1987-05-26 Yamanouchi Pharmaceut Co Ltd 置換フエネチルアミン誘導体の製造法
JPH066565B2 (ja) * 1986-07-21 1994-01-26 山之内製薬株式会社 光学活性なベンゼンスルホンアミド誘導体の製造法
US4971990A (en) * 1988-02-19 1990-11-20 Hokuriku Pharmaceutical Co., Ltd. Phenoxyethylamine derivatives, for preparing the same and composition for exhibiting excellent α1 -blocking activity containing the same
EP0416804B1 (de) * 1989-09-04 1993-05-26 Yamanouchi Pharmaceutical Co. Ltd. Äusserlich anzuwendende Amusulosin enthaltende Arzneizubereitung
US5288759A (en) * 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
WO1995002419A1 (en) * 1993-07-14 1995-01-26 Yamanouchi Pharmaceutical Co., Ltd. Remedy for urination disorder accompanying prostatic hypertrophy
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
FR2737494B1 (fr) * 1995-08-04 1997-08-29 Synthelabo Derives de benzenesulfonamide, leur preparation et leur application en therapeutique
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
AU2556897A (en) * 1996-04-12 1997-11-07 Beth Israel Deaconess Medical Center Diabetic supplement bar
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
MXPA00010805A (es) * 1998-05-06 2002-05-08 Univ Duke Metodo para el tratamiento de sindromes de la vejiga y del tracto urinario inferior.
TW536402B (en) 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
EP1604653A1 (de) 1998-09-30 2005-12-14 Takeda Pharmaceutical Company Limited Acetylcholinesterase-Inhibitoren zur Verbesserung der Ausscheidungskraft der Harnblase
KR20020016944A (ko) * 1999-08-09 2002-03-06 오노다 마사요시 하부 요로증 치료용 의약 조성물
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
KR100421508B1 (ko) * 2001-08-07 2004-03-09 김정한 항균 및 항진균 활성을 갖는 신규한 펜에틸아민 유도체와이의 염
US6835853B2 (en) 2001-10-31 2004-12-28 Synthon Bv Process for resolution of tamsulosin and compounds, compositions, and processes associated therewith
PT1443917E (pt) * 2001-11-07 2006-06-30 Synthon Bv Comprimidos de tamsulosina
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
CA2477088A1 (en) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
JP2005524693A (ja) 2002-04-24 2005-08-18 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 良性前立腺増殖症の治療又は急性尿閉の長期予防用の医薬組成物
US6894188B1 (en) 2002-04-30 2005-05-17 Ranbaxy Laboratory Limited Tamsulosin derivative
ES2200699B1 (es) * 2002-07-12 2005-10-01 Ragactives, S.L Procedimiento para la separacion de r(-) y s(+)-5-(2-((2-(etoxifenoxi)etil)amino)propil-2-metoxibenceno-sulfonamida.
WO2004016582A1 (en) * 2002-08-14 2004-02-26 Natco Pharma Limited An improved process for the preparation of tamsulosin hydrochloride
PL375713A1 (en) 2002-08-19 2005-12-12 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US7018658B2 (en) 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
DE60332387D1 (de) 2002-12-13 2010-06-10 Warner Lambert Co Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
US20060173214A1 (en) * 2002-12-26 2006-08-03 Dubey Sushil K Process for the preparation of enantiomerically pure (r) or (s)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide
KR100503639B1 (ko) 2003-02-12 2005-07-26 보령제약 주식회사 탐술로신의 정제 방법
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
DE10315702A1 (de) * 2003-04-07 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Arzneitmittelkombinationen zur Behandlung von gutartiger Prostatahyperplasie oder zur Behandlung von abakterieller Prostatitis
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
BRPI0410840A (pt) * 2003-05-30 2006-07-04 Ranbaxy Lab Ltd derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
CA2451175A1 (en) * 2003-11-26 2005-05-26 Torcan Chemical Ltd. Process for the preparation of tamsulosin
KR100596373B1 (ko) * 2003-12-09 2006-07-04 씨제이 주식회사 광학적으로 순수한 펜에틸 아민 유도체의 제조방법
SI21655A (sl) * 2003-12-29 2005-06-30 LEK farmacevtska dru�ba d.d. Sinteza optično čistega (R)-5-(2-aminopropil)-2-metoksibenzensulfonamida
SI21656A (sl) * 2003-12-29 2005-06-30 LEK farmacevtska družba d.d. Priprava (R)-5-(2-(2-(2-etoksifenoksi) etilamino)-1-propil)-2-metoksibenzensulfonamida hidroklorida z visoko kemijsko čistoto
EP1568369A1 (de) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam zur Behandlung von Atemwegserkrankungen bei Schweinen
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
WO2006004093A1 (ja) * 2004-07-07 2006-01-12 Hamari Chemicals, Ltd. 光学活性フェニルプロピルアミン誘導体の製法
CN100545148C (zh) * 2004-08-16 2009-09-30 神隆新加坡私人有限公司 一种抗良性前列腺肥大药物坦索罗辛之合成方法
US7238839B2 (en) 2004-10-07 2007-07-03 Divi's Laboratories Limited Process for the resolution of racemic (R,S) -5-(2-(2-(2- ethoxyphenoxy) ethylamino)Propyl)-2-methoxybenzene sulfonamide (tamsulosin), its novel R and S isomers and their salts and processes for their preparation
PT103216B (pt) * 2004-12-06 2010-05-19 Hovione Farmaciencia S A Preparação de tamsulosin
CA2588017A1 (en) * 2004-12-13 2006-06-22 Boehringer Ingelheim Pharmaceuticals, Inc. Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
ES2258394B1 (es) * 2004-12-31 2007-12-01 Quimica Sintetica, S.A. Procedimiento enzimatico para la preparacion de un compuesto intermedio y su uso en la sintesis de tamsulosina clorhidrato.
WO2006100557A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
CA2602383A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
AR057290A1 (es) * 2005-05-04 2007-11-28 Medichem Sa Proceso para la preparacion de tamsulosina
US20090137844A1 (en) * 2005-06-15 2009-05-28 Fermion Oy Crystallization process
WO2007017752A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US8273918B2 (en) * 2005-09-12 2012-09-25 Avrobindo Pharma Ltd. Process for preparing tamsulosin hydrochloride
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
KR101329112B1 (ko) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
WO2007131804A1 (en) 2006-05-17 2007-11-22 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
CN101494980A (zh) * 2006-07-14 2009-07-29 兰贝克赛实验室有限公司 HMG-CoA还原酶抑制剂的多晶型形式及其应用
EP2049117A4 (de) * 2006-08-08 2010-08-25 Auspex Pharmaceuticals Inc Zubereitung und verwendung substituierter chinazolinverbindungen mit alpha-adrenerger blokierungswirkung
US20080113030A1 (en) * 2006-11-09 2008-05-15 Ching-Fen Hsiao Sustained release tamsulosin formulations
CN101190890B (zh) * 2006-11-30 2011-04-27 江苏豪森药业股份有限公司 5-[(2r)-[2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙基]氨基]丙基]-2-甲氧基苯磺酰胺
EP2094643B1 (de) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf-erkrankungen
US20080312328A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched tamsulosin
US20090004284A1 (en) * 2007-06-26 2009-01-01 Watson Pharmaceuticals, Inc. Controlled release tamsulosin hydrochloride formulation
WO2009013846A1 (ja) 2007-07-20 2009-01-29 Astellas Pharma Inc. 前立腺肥大に伴う下部尿路症状の改善用医薬組成物
CA2709727A1 (en) 2007-12-21 2009-07-02 Astellas Pharma Inc. Pharmaceutical composition for improving lower urinary tract symptoms
EP2181707A1 (de) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Kombinierte Verwendung eines alpha-adrenergischen Rezeptorantagonisten und eines Antimuskarinmittels
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
DK2394648T3 (en) 2009-02-04 2016-09-26 Astellas Pharma Inc A pharmaceutical composition for oral administration
EP2255793A1 (de) 2009-05-28 2010-12-01 Krka Tovarna Zdravil, D.D., Novo Mesto Pharmazeutische Zusammensetzung mit Tamsulosin
PL4378443T3 (pl) 2009-10-12 2025-09-08 Boehringer Ingelheim Vetmedica Gmbh Pojemniki na kompozycje zawierające meloksykam
CN102050766B (zh) * 2009-11-03 2013-08-07 安徽省新星药物开发有限责任公司 一种盐酸氨磺洛尔的合成方法
CA2791805A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
EP2986599A1 (de) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamid-derivate zur behandlung von herz-kreislauf-erkrankungen
BR102013020508B1 (pt) 2013-08-12 2021-01-12 Ems S/A. Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
ES2555485T1 (es) 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN106478467B (zh) * 2016-10-13 2018-07-13 深圳万和制药有限公司 制备稳定的盐酸坦索罗辛的方法
EP3697392B1 (de) 2017-10-17 2023-11-15 Synthon B.V. Tabletten mit tamsulosin und solifenacin
EP3473244A1 (de) 2017-10-20 2019-04-24 Veru Inc. Orales tamsulosinhydrochlorid mit kontrollierter freisetzung
EP3473245A1 (de) 2017-10-20 2019-04-24 Veru Inc. Orales tamsulosinhydrochlorid mit kontrollierter freisetzung
CN108037196B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种3-硝基-4-[[(四氢-2h-吡喃-4-基)甲基]氨基]苯磺酰胺的检测方法
CR20210441A (es) 2019-01-18 2022-03-11 Astrazeneca Ab Inhibidores de la pcsk9 y métodos de uso de los mismos
CN117049972B (zh) * 2023-08-25 2025-09-16 东莞理工学院 一种小分子酮肽的制备方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3701808A (en) * 1967-12-21 1972-10-31 Allen & Hanburys Ltd Phenylethanolamines
SE368197B (de) * 1968-11-18 1974-06-24 Pfizer
US3878212A (en) * 1970-04-28 1975-04-15 Clemens Rufer Blood sugar lowering sulfamoyl pyrimidines and asymmetrical carbon atom
US4137328A (en) * 1970-07-18 1979-01-30 Pfizer Inc. Phenyl-alkanolamine, alkylamine and α-aminoalkyl ketone derivatives as heart stimulants
US3711545A (en) * 1971-02-23 1973-01-16 Smith Kline French Lab Alpha-aminoalkyl-4-hydroxy-3-sulfamoylaminobenzyl alcohols
DE2115926C3 (de) * 1971-04-01 1978-05-03 C.H. Boehringer Sohn, 6507 Ingelheim 1 -(4-Hydroxy-3-dimethylaminosuIfamidophenyI)-2-aminoäthanderivate, Verfahren zu ihrer Herstellung und diese enthaltende Mittel
US3860647A (en) * 1973-08-20 1975-01-14 Smithkline Corp {60 -Aminomethyl-4-hydroxy-3-sulfamyl-benzyl alcohols and 4-hydroxy-3-sulfamyl phenethylamines
GB1593651A (en) * 1977-02-03 1981-07-22 Allen & Hanburys Ltd Amides
CA1147342A (en) * 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives
US4558156A (en) * 1980-02-08 1985-12-10 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl-substituted phenethylamine derivatives
JPS56110665A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
DE3110573A1 (de) * 1981-03-18 1982-10-21 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n- und o-substituierten di- und/oder polyurethanen
JPS5950671B2 (ja) * 1982-08-26 1984-12-10 山之内製薬株式会社 フェニルエタノ−ルアミン誘導体およびその製造法
US4558106A (en) * 1983-03-29 1985-12-10 Union Carbide Corporation Polymerization process using metal formate to reduce the color of thermoplastic copolymers

Also Published As

Publication number Publication date
JPS56110665A (en) 1981-09-01
NL950014I2 (nl) 1997-01-06
US4761500A (en) 1988-08-02
SU1082320A3 (ru) 1984-03-23
EP0034432A2 (de) 1981-08-26
LU90000I2 (fr) 1997-03-04
EP0034432A3 (en) 1982-03-24
ES8201966A1 (es) 1982-01-01
US4987152A (en) 1991-01-22
EP0034432B1 (de) 1984-04-25
PT72460A (en) 1981-03-01
GR73827B (de) 1984-05-04
MX6859E (es) 1986-09-08
IE50862B1 (en) 1986-08-06
UA5981A1 (uk) 1994-12-29
JPS6252742B2 (de) 1987-11-06
MX9203592A (es) 1992-07-31
ES499224A0 (es) 1982-01-01
NL950014I1 (nl) 1996-12-02
UA5990A1 (uk) 1994-12-29
US4731478A (en) 1988-03-15
SU1181540A3 (ru) 1985-09-23
SU1248533A3 (ru) 1986-07-30
AU541720B2 (en) 1985-01-17
AR227533A1 (es) 1982-11-15
IE810236L (en) 1981-08-08
CA1177849A (en) 1984-11-13
AU6689681A (en) 1981-08-13
UA5980A1 (uk) 1994-12-29
AR230433A1 (es) 1984-04-30
US4703063A (en) 1987-10-27
US4868216A (en) 1989-09-19
DE3163257D1 (en) 1984-05-30
DE19675042I2 (de) 2001-06-13
US4373106A (en) 1983-02-08
PT72460B (en) 1982-02-04

Similar Documents

Publication Publication Date Title
ATE7223T1 (de) Durch sulfamoylgruppen substituierte phenethylamin-derivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE2616T1 (de) 1-aryl-2-acylamido-3-fluor-1-propanole, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
FI792009A7 (fi) 3-aminopropoksiaryylijohdannaisia, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset.
FI813734A7 (fi) Farmaseuttiset koostumukset.
FI813862A7 (fi) Uusia 8-aryylialkyyli-3- fenyyli-3- nortropanoleja, niiden happoadditiosuoloja, näitä sisältäviä lääkeainelääkeaineita ja menetelmiä niiden valmistamiseksi.
FI830163A7 (fi) Fenyylietyleeni-johdannaisia, niiden valmistus ja käyttö lääkeaineina.
FI821167A0 (fi) Lokalt anvaendbara farmaceutiska kompositioner, som innehaoller antiinflammatoriska steroider
IL64344A (en) Substituted alkanolamine derivatives,their preparation and pharmaceutical compositions comprising the same
IT8021370A0 (it) Derivati teofillinmetildiossolanici, procedimenti per la loro preparazione e relative composizioni farmaceutiche.
DE3578597D1 (de) 4-phenylphthalazin-derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
IT8023262A0 (it) Composizioni farmaceutiche contenenti estratti di edera rampicante.
FI822671A7 (fi) Aminoglykosidijohdannaisia, menetelmiä niiden valmistamiseksi, niitä sisältäviä farmaseuttisia koostumuksia ssekä tällaisia johdannaisia kä ytettäviksi lääkeaineina.
IT8123541A0 (it) Composti citostatici, procedimento per la loro preparazione e composizioni farmaceutiche contenti gli stessi.
IT8023101A0 (it) Composizione farmaceutica per uso terapeutico, per uso diagnostico e quale integratore alimentare.
IL62970A0 (en) Substituted phenoxy-aminopropanol derivatives,their preparation and pharmaceutical compositions containing them
FI803908A7 (fi) Uusia pyrrolobentsotriatsepiineja, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset.
FI810344A7 (fi) Uusia indaanijohdannaisia, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineina ja mainittuja johdajohdannaisia sisältävät farmaseuttiset koostumukset.
FI793035A7 (fi) Uudet 2-substituoidut-3-heterosyklyyli- indolit, niiden valmistaminen ja niitä sisältävät farmaseuttiset seoksseokset.
ATE3425T1 (de) Hypoglykaemische guanylamidine, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE3635T1 (de) Mycoplanecin-derivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE18055T1 (de) Tylosinderivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
FI831008A7 (fi) Pyridoni-2- johdannaisia, menetelmiä niiden valmistamiseksi ja niitä sisältäviä lääkeaineita.
ATE4666T1 (de) Eburnan-derivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
IT8319993A0 (it) Composizioni farmaceutiche contenenti composti a scheletro flavanonico, procedimento per lapreparazione di detti composti e nuovi composti ottenuti.
ATE11772T1 (de) Neue prostaglandine, ihre herstellung und pharmazeutische kompositionen.